MedTrace Logo

New Horizons for the Treatment of Cardiomyopathy in Children

NCT04893629 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-02-20

No results posted yet for this study

Summary

Collecting mono nuclear cells from the patient's blood after a course of granulocyte stimulation then injecting them into the weak heart muscle measuring the heart function at the beginning and after 2.4.6 months to assess the improvement due to this procedure, by comparing these patients to patients with the same condition treated the classic way.

Conditions

Interventions

BIOLOGICAL

mono nuclear cells injection

trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group

DRUG

Digoxin+furosemide+captopril

classical heart failure medical treatment

Sponsors & Collaborators

  • Damascus University

    lead OTHER

Principal Investigators

  • samir srour, prof · membership of the French society of the pediatric cardiology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • Syria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893629 on ClinicalTrials.gov